Intramuscular 17α-hydroxyprogesterone caproate to decrease preterm delivery in women with placenta praevia: a randomised controlled trial

References

• Alsayegh E, Barrett J, Melamed N. 2017. 725: optimal timing of antenatal corticosteroids in women with bleeding placenta previa. American Journal of Obstetrics and Gynecology 216:S423.
   Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists (ACOG). 2016. Practice Bulletin No. 171: management of preterm labor. Obstetrics and gynecology, 128(4), p.e155. Available from: https://journals.lww.com/greenjournal/FullText/2016/10000/Practice_Bulletin_No__171__Management_of_Preterm.61.aspx#pdf-link
   Google Scholar
• Ananth CV, Smulian JC, Vintzileos AM. 2003. The effect of placenta previa on neonatal mortality: a population-based study in the United States, 1989 through 1997. American Journal of Obstetrics and Gynecology 188:1299–1304.
   PubMed Web of Science ®Google Scholar
• Anjula B. 2013. Study of use of progesterone for symptomatic placenta in a tertiary care teaching hospital. Indian Journal of Basic and Applied Medical Research 3:340–345.
   Google Scholar
• Arulkumaran S. 2009. Best practice in labour and delivery. Cambridge (UK): Cambridge University Press. p. 142–146. ISBN 978-0-521-72068-7.
   Google Scholar
• Bernal AL. 2007. The regulation of uterine relaxation. Seminars in Cell and Developmental Biology 18:340–347.
   PubMed Web of Science ®Google Scholar
• Bose DA, Assel BG, Hill JB, Chauhan SP. 2011. Maintenance tocolytics for preterm symptomatic placenta previa: a review. American Journal of Perinatology 28:045–050.
   PubMed Web of Science ®Google Scholar
• Collins SL, Ashcroft A, Braun T, Calda P, Langhoff-Roos J, Morel O, et al. 2016. Proposal for standardized ultrasound descriptors of abnormally invasive placenta (AIP). Ultrasound in Obstetrics and Gynecology 47:271–275.
   PubMed Web of Science ®Google Scholar
• Dashe JS, McIntire DD, Ramus RM, Santos-Ramos R, Twickler DM. 2002. Persistence of placenta previa according to gestational age at ultrasound detection. Obstetrics and Gynecology 99:692–697.
   PubMed Web of Science ®Google Scholar
• Fishman SG, Chasen ST, Maheshwari B. 2011. Risk factors for preterm delivery with placenta previa. Journal of Perinatal Medicine 40:39–42.
   PubMed Web of Science ®Google Scholar
• Getahun D, Oyelese Y, Salihu HM, Ananth CV. 2006. Previous cesarean delivery and risks of placenta previa and placental abruption. Obstetrics and Gynecology 107:771–778.
   PubMed Web of Science ®Google Scholar
• Hong DH, Kim E, Kyeong KS, Hong SH, Jeong EH. 2016. Safety of cesarean delivery through placental incision in patients with anterior placenta previa. Obstetrics and Gynecology Science 59:103–109.
   PubMedGoogle Scholar
• How HY, Sibai BM. 2009. Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety. Therapeutics and Clinical Risk Management 5:55.
   PubMedGoogle Scholar
• Jauniaux ERM, Alfirevic Z, Bhide AG, Belfort MA ,Burton GJ ,Collins SL, et al. 2018. Placenta praevia and placenta accreta: diagnosis and management. Green-top guideline no. 27a. International Journal of Obstetrics and Gynaecology 126:e1–e48.
   Google Scholar
• Manuck TA. 2017. Refining pharmacologic research to prevent and treat spontaneous preterm birth. Frontiers in Pharmacology 8:118.
   PubMed Web of Science ®Google Scholar
• Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. 2003. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. New England Journal of Medicine 348:2379–2385.
   PubMed Web of Science ®Google Scholar
• Mustafa SA, Brizot ML, Carvalho MH, Watanabe L, Kahhale S, Zugaib M. 2002. Transvaginal ultrasonography in predicting placenta previa at delivery: a longitudinal study. Ultrasound in Obstetrics and Gynecology 20:356–359.
   PubMed Web of Science ®Google Scholar
• Oler E, Eke AC, Hesson A. 2017. Meta‐analysis of randomized controlled trials comparing 17α‐hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery. International Journal of Gynecology and Obstetrics 138:12–16.
   PubMed Web of Science ®Google Scholar
• Petpichetchian C, Pranpanus S, Suntharasaj T, Kor-anantakul O, Hanprasertpong T. 2018. Comparison of transabdominal and transvaginal sonography in the diagnosis of placenta previa. Journal of Clinical Ultrasound 46:386–390.
   PubMed Web of Science ®Google Scholar
• Predanic M, Perni SC, Baergen RN, Jean-Pierre C, Chasen ST, Chervenak FA, et al. 2005. A sonographic assessment of different patterns of placenta previa “migration” in the third trimester of pregnancy. Journal of Ultrasound in Medicine 24:773–780.
   PubMed Web of Science ®Google Scholar
• Quant HS, Friedman AM, Wang E, Parry S, Schwartz N. 2014. Transabdominal ultrasonography as a screening test for second-trimester placenta previa. Obstetrics and Gynecology 123:628–633.
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynaecologists (RCOG). 2011. Placenta praevia, placenta praevia accreta and vasa praevia: diagnosis and management. Green-top Guideline No. 27. London: RCOG. Available from: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg27/
   Google Scholar
• Saccone G, Suhag A, Berghella V. 2015. 17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials. American Journal of Obstetrics and Gynecology 213:16–22.
   PubMed Web of Science ®Google Scholar
• Saghafi N, Khadem N, Mohajeri T, Shakeri MT. 2011. Efficacy of 17α‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research 37:1342–1345.
   PubMed Web of Science ®Google Scholar
• Sekiguchi A, Nakai A, Kawabata I, Hayashi M, Takeshita T. 2013. Type and location of placenta previa affect preterm delivery risk related to antepartum hemorrhage. International Journal of Medical Sciences 10:1683.
   PubMed Web of Science ®Google Scholar
• Sharma A, Suri V, Gupta I. 2004. Tocolytic therapy in conservative management of symptomatic placenta previa. International Journal of Gynecology and Obstetrics 84:109–113.
   PubMed Web of Science ®Google Scholar
• Simhan HN, Caritis SN. 2007. Prevention of preterm delivery. The New England Journal of Medicine 357:477–487.
   PubMed Web of Science ®Google Scholar
• Singh P, Jain SK. 2015. Evaluation of the effect of progesterone and placebo in parturient of symptomatic placenta previa: a prospective randomized control study. International Journal of Scientific Study 3:69–72.
   Google Scholar
• Sowjanya Kumari J, Bhavani V, Swetha, Himabindu, Madhumitha M. 2016. Placental migration in mid trimester low-lying placenta. Journal of Dental and Medical Sciences 15:150–156.
   Google Scholar
• Tuzović L, Djelmis J, Ilijić M. 2003. Obstetric risk factors associated with placenta praevia development: case-control study. Croatian Medical Journal 44:728–733.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (US-FDA). 2018. Updated statement on compounded version of hydroxyprogesterone caproate. Available from: https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/ucm402614.htm
   Google Scholar
• Vahanian SA, Lavery JA, Ananth CV, Vintzileos A. 2015. Placental implantation abnormalities and risk of preterm delivery: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology 213:S78–S90.
   PubMed Web of Science ®Google Scholar
• Verspyck E, de Vienne C, Muszynski C, Bubenheim M, Chanavaz-Lacheray I, Dreyfus M, et al. 2017. Maintenance Nifedipine therapy for preterm symptomatic placenta previa: a randomized, multicenter, double-blind, placebo-controlled trial. PLoS One 12:e0173717.
   PubMed Web of Science ®Google Scholar
• Vidaeff AC, Belfort MA. 2013. Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birth. Patient Preference and Adherence 7:683.
   PubMed Web of Science ®Google Scholar